OncoMatch/Clinical Trials/NCT07223307
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Is NCT07223307 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for liver cancer.
Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radioembolization
Prior treatment with radioembolization
Cannot have received: radiotherapy
Exception: if overlapping with study treatment site
Prior radiotherapy overlapping with study treatment site
Lab requirements
Liver function
child-pugh a status
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify